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Abstract
 
Gene expression profiling has revealed that diffuse large B cell lymphoma (DLBCL) consists of
at least two distinct diseases. Patients with one DLBCL subtype, termed activated B cell–like
(ABC) DLBCL, have a distinctly inferior prognosis. An untapped potential of gene expression
profiling is its ability to identify pathogenic signaling pathways in cancer that are amenable to
therapeutic attack. The gene expression profiles of ABC DLBCLs were notable for the high
expression of target genes of the nuclear factor (NF)-
 
 
 
B transcription factors, raising the possi-
bility that constitutive activity of the NF-
 
 
 
B pathway may contribute to the poor prognosis of
these patients. Two cell line models of ABC DLBCL had high nuclear NF-
 
 
 
B DNA binding
activity, constitutive I
 
 
 
B kinase (IKK) activity, and rapid I
 
 
 
B
 
 
 
 degradation that was not seen
in cell lines representing the other DLBCL subtype, germinal center B-like (GCB) DLBCL.
Retroviral transduction of a super-repressor form of I
 
 
 
B
 
 
 
 or dominant negative forms of
IKK
 
 
 
 was toxic to ABC DLBCL cells but not GCB DLBCL cells. DNA content analysis
showed that NF-
 
 
 
B inhibition caused both cell death and G1-phase growth arrest. These find-
ings establish the NF-
 
 
 
B pathway as a new molecular target for drug development in the most
clinically intractable subtype of DLBCL and demonstrate that the two DLBCL subtypes de-
fined by gene expression profiling utilize distinct pathogenetic mechanisms.
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apoptosis
 
Introduction
 
The Rel/nuclear factor (NF)
 
*
 
-
 
 
 
B transcription factors inte-
grate diverse intracellular signaling pathways that are acti-
vated during normal cellular differentiation and during im-
mune responses (1–4). NF-
 
 
 
B–dependent transcriptional
activity is mediated by dimers of NF-
 
 
 
B family members
(p50/105, p52/100, p65/RelA, RelB, or c-Rel), and is reg-
ulated by members of the I
 
 
 
B family of inhibitors, princi-
pally I
 
 
 
B
 
 
 
, which binds to NF-
 
 
 
B dimers and retains them
in the cytoplasm. Upon phosphorylation by the I
 
 
 
B kinase
(IKK) complex, I
 
 
 
B
 
 
 
 is targeted for ubiquitination and
proteasomal degradation, and released NF-
 
 
 
B dimers can
translocate to the nucleus and activate transcription of target
genes (3). NF-
 
 
 
B target genes encode diverse mediators of
immune responses as well as regulators of cellular prolifera-
tion and apoptosis. The expression of these target genes var-
ies, in part, with the cell type in which NF-
 
 
 
B is activated.
NF-
 
 
 
B activity is critical for normal B cell development
and survival, and distinct NF-
 
 
 
B heterodimers participate
in different stages of B cell differentiation and activation
(for a review, see reference 5). NF-
 
 
 
B transcriptional activ-
ity in B cells primarily involves heterodimers between one
of the transactivating subunits (c-Rel or RelA) and one of
the nontransactivating subunits (p50, the processed form of
NF-
 
 
 
B1 or p52, the processed form of NF-
 
 
 
B2). Mature
murine B cell lines show constitutive low-level NF-
 
 
 
B ac-
tivity, chiefly due to heterodimers of p50 and c-Rel (6).
Targeted deletion of 
 
c-rel
 
 does not affect the number of ma-
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Abbreviations used in this paper:
 
 ABC, activated B cell–like; BCR, B
cell receptor; CHX, cycloheximide; DLBCL, diffuse large B cell lym-
phoma; EGFP, enhanced green fluorescent protein; EMSA, electro-
phoretic mobility shift assay; GCB, germinal center B-like; HA, hemag-
glutinin; IKK, I
 
 
 
B kinase; NF, nuclear factor; PI, PMA and ionomycin. 
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ture B cells in mice, but such studies are complicated by
functional redundancy of NF-
 
 
 
B family members. In mice
lacking both 
 
c-rel
 
 and 
 
rela
 
, mature B cells fail to develop due
to accelerated apoptosis upon emergence of immature B
cells from the bone marrow into the periphery (7). Imma-
ture B cells in such mice fail to undergo normal increases in
the antiapoptotic protein, BCL-2, and its family member,
A1/Bfl-1. Furthermore, transgenic overexpression of BCL-2
in 
 
c-rel
 
 and 
 
rela
 
 double mutant mice allows for partial mat-
uration of B cells in the periphery (7). Similarly, resting B
cells from mice lacking NF-
 
 
 
B1 show an increased rate of
apoptosis, which can be prevented by enforced expression
of BCL-2 (10). It is possible that the prosurvival function of
basal NF-
 
 
 
B activity in mature B cells is the result of con-
stitutive signaling through the B cell receptor (BCR),
given that NF-
 
 
 
B is activated by BCR engagement and
acute deletion of the BCR leads to rapid disappearance of
mature B cells in mice (8).
Mature B cells also require acute increases in NF-
 
 
 
B ac-
tivity in order to proliferate and survive in response to mi-
togens. Mice with inactivating mutations in 
 
c-rel
 
 and 
 
rela
 
have normal numbers of mature B cells, but these cells are
defective in their proliferative responses to BCR signaling
and to lipopolysaccharide (9–11). The proliferative defect
in c-Rel–deficient B cells is reflected in a block at the G1
stage of the cell cycle (10, 11). A possible mediator of NF-
 
 
 
B proliferative responses is IRF-4, a transcription factor
that is required for proliferation of B and T lymphocytes
(12) and that is induced by binding of c-Rel to NF-
 
 
 
B
motifs in its promoter (13). However, optimal increases in
cell numbers after BCR stimulation also involve inhibition
of apoptosis, and NF-
 
 
 
B activity has again been implicated.
c-Rel–deficient B cells die by apoptosis in response to
BCR ligation (10, 14). The BCL-2 family member A1 is a
target of NF-
 
 
 
B, and is induced after BCR stimulation
(14). Ectopic expression of A1 in c-Rel–deficient B cells
rescues the cells from apoptosis (14); BCL-2 provides simi-
lar protection from apoptosis (10, 14), but does not prevent
the G1-phase block to proliferation (10). Thus, NF-
 
 
 
B
controls both proliferation and apoptosis in B cells to max-
imize the response to mitogens.
NF-
 
 
 
B activation by mitogenic stimuli is normally self-
limited, but constitutive nuclear NF-
 
 
 
B has been found in
several types of cancers, raising the possibility that the anti-
apoptotic and/or pro-proliferative effects of NF-
 
 
 
B may
contribute to malignant transformation or progression (for
a review, see references 15 and 16). For example, in cell
lines and some primary tumors of Hodgkin’s disease, muta-
tions of the I
 
 
 
B
 
 
 
 gene result in its functional inactivation
and the accumulation of p50/RelA heterodimers in the
nucleus (for a review, see reference 17). In Hodgkin’s dis-
ease cell lines, inhibition of this NF-
 
 
 
B activity by genetic
means reduces cell viability (18–20). Likewise, transforma-
tion of B cells by Epstein-Barr virus induces NF-
 
 
 
B activ-
ity, and this activity is necessary for survival of these cells in
vitro (21). In other types of lymphoid malignancies, consti-
tutive NF-
 
 
 
B activity can occur occasionally due to trans-
locations involving the NF-
 
 
 
B2 gene that disrupt its
COOH terminus (22, 23), or by amplification of the 
 
c-rel
 
locus (24, 25). While these various lines of investigation
have led to the notion that NF-
 
 
 
B activation in human
cancer may be of pathogenetic significance, more work is
needed to demonstrate a direct link between NF-
 
 
 
B activ-
ity and clinical outcome.
Diffuse large B cell lymphoma (DLBCL), the most com-
mon type of nonHodgkin’s lymphoma, presents an impor-
tant clinical challenge given that only 40% of these patients
are cured by conventional chemotherapy. The heteroge-
neous outcomes of these patients is due, in part, to the fact
that this diagnostic category is comprised of at least two
distinct disease entities that differ in their outcome after
chemotherapy (26). This conclusion was drawn from an
analysis of gene expression in DLBCL tumors using DNA
microarrays that revealed two large DLBCL subgroups that
differed in the expression of hundreds of genes. Further-
more, the gene expression profiles of these DLBCL sub-
groups resembled the profiles of normal B cells at different
stages of differentiation, for which they were named. Ger-
minal center B-like (GCB) DLBCLs expressed the “signa-
ture” genes of normal tonsillar germinal center B cells. Ac-
tivated B cell–like (ABC) DLBCLs did not express the
germinal center B cell signature genes but instead constitu-
tively expressed genes that are normally induced in human
blood B cells after BCR stimulation.
In this study, we investigated which signaling pathways
might contribute to the biological and clinical differences
between GCB and ABC DLBCLs. A survey of the gene
expression profiles of these two DLBCL subtypes revealed
that several genes expressed characteristically in ABC DLB-
CLs are known NF-
 
 
 
B target genes. We show that two
DLBCL cell lines derived from ABC DLBCLs have NF-
 
 
 
B activation due to high constitutive IKK activity and
I
 
 
 
B
 
 
 
 degradation. Most importantly, abrogation of NF-
 
 
 
B
activity was toxic to these ABC DLBCL cells and not to
cell lines derived from GCB DLBCLs. This finding dem-
onstrates that the two DLBCL subtypes have distinct
pathogenetic mechanisms and establishes constitutive NF-
 
 
 
B activation as a target for therapeutic intervention in
ABC DLBCLs.
 
Materials and Methods
 
Cell Lines.
 
All cell lines were maintained at 37
 
 
 
C in 5% car-
bon dioxide. ABC DLBCL lines OCI-Ly3 and OCI-Ly10, and
the GCB DLBCL line OCI-Ly7, were maintained in Iscove’s
modified essential medium with 
 
 
 
-mercaptoethanol (55 
 
 
 
M),
penicillin (50 U/ml), streptomycin (50 
 
 
 
g/ml), and 20% heparin-
ized normal human plasma. All other cell lines were maintained
in RPMI 1640 medium with 
 
L
 
-glutamine, Hepes, penicillin,
streptomycin, and 10% FCS. As a control, SUDHL-6 cells were
also cultured in the same medium as the OCI cell lines, and no
increase was observed in either I
 
 
 
B
 
 
 
 degradation or NF-
 
 
 
B
DNA binding activity (data not shown).
 
Microarray Analysis of Gene Expression.
 
DNA microarray anal-
ysis of gene expression was performed using Lymphochip mi-
croarrays, as described previously (26). Briefly, mRNA from an
experimental sample was labeled with Cy5 dUTP in a first strand 
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cDNA reaction, and a reference cDNA probe, labeled with Cy3
dUTP, was prepared using mRNA from a pool of nine lym-
phoma cell lines. After hybridization of these two cDNA probes
to a Lymphochip DNA microarray (27), the arrays were washed
and bound fluorescent probe was detected using an Axon Gene-
Pix Scanner. The ratio of the pixel intensities for Cy5 and Cy3
fluorescence was calculated for each array element. For a given
gene, these ratios were median-centered before display using a
color scheme as described previously (28). Data for Figs. 1 A and
C were taken from http://llmpp.nih.gov/lymphoma (26).
 
Western Blot Analyses.
 
Total cell extracts were prepared for
Western blotting as described previously (29). I
 
 
 
B
 
 
 
 blots were
probed with antibodies to full-length hI
 
 
 
B
 
 
 
 (30). Equivalent
amounts of cell extract were run in each lane. IKK
 
 
 
 blots were
probed with monoclonal anti-full length IKK
 
 
 
 (BD PharMin-
gen). BCL–XL was detected with mAb (H-5; Santa Cruz Bio-
technology, Inc.) recognizing the COOH terminus.
 
Electrophoretic Mobility Shift Assays.
 
Nuclear extracts were
prepared and electrophoretic mobility shift assays (EMSAs) per-
formed using the palindromic NF-
 
 
 
B binding sequence as de-
scribed previously (31), along with SP1 and Oct-1 probes
(Promega). Equivalent amounts of nuclear extract (10 
 
 
 
g) were
analyzed in each assay. Antibodies for supershift EMSAs were
rabbit polyclonal antibodies raised against the following peptides
conjugated to Keyhole Limpet Hemocyanin: p50, NH
 
2
 
-terminal
12 amino acids of human p50; p65/RelA, amino acids 2–15 of
human p65/RelA; c-Rel, amino acids 573–587 of human c-Rel.
 
IKK Assay.
 
Endogenous IKK complex in cell extracts was
immunoprecipitated on Protein G-sepharose beads (Pharmacia 
 
 
 
Bind Plus) using anti-IKK
 
 
 
 (SC8330; Santa Cruz Biotechnology,
Inc.) as primary antibody. Kinase activity of the immune complex
was assayed as described (29) using Glutathione S-transferase
(GST)-I
 
 
 
B
 
 
 
 (amino acids 1–72) and GST-I
 
 
 
B
 
 
 
 S32G/S36A
(amino acids 1–72) (2 
 
 
 
g) as substrates (provided by H. Ellinger-
Ziegelbauer, National Institutes of Health, Bethesda, MD). Assays
were performed with equivalent amounts of IKK immune com-
plex as judged by Western blots of the complexes for IKK
 
 
 
.
 
Retroviral Constructs and Transductions.
 
The vXY-Puro retro-
viral vector was prepared from pBMN-Ires-Lyt2 (provided by G.
Nolan, Stanford University, Stanford, CA) by exchanging a
puromycin resistance cassette from internal ribosomal entry site-
Puro (pIRES; CLONTECH Laboratories, Inc.) for the coding
region of mouse CD8a (Lyt-2), as reported previously (32). The
enhanced green fluorescent protein (EGFP)-F vector was simi-
larly prepared, using NcoI and XhoI to excise the coding region
of farnesylated EGFP from pEGFP-F (CLONTECH Laborato-
ries, Inc.). Human I
 
 
 
B
 
 
 
 wild-type and S32G/S36A coding re-
gions, excised from a pcDNA3.1 vector (Invitrogen) after addi-
tion of an NH
 
2-terminal FLAG epitope by PCR by J. Mueller,
were as described previously (30). NH2 terminus FLAG-tagged
A1/Bfl-1 was subcloned from pcDNA3 provided by A. Karsan.
BCL–XL and BCL-2 were provided in pcDNA3 by R. Youle
and Y.-T. Hsu, and were subcloned after addition of an NH2
terminus hemagglutinin (HA) epitope via interim subcloning.
NH2 terminus HA-tagged IKK  was obtained by PCR from a
human spleen library (CLONTECH), and K44A or S177A/
S181A mutations were introduced by site-directed mutagenesis.
Transductions were performed by spin infection as described
previously (33).
Survival Analysis of Transduced Cells. For enumeration of live
cells after vLyt-2 retroviral transductions, measured aliquots of
cultures were centrifuged and the cell pellets stained on ice for 15
min after resuspension in 10  L of a mixture of FITC-conjugated
anti–mouse CD8a (BD PharMingen; 5  g/ml) and ethidium ho-
modimer-1 (Molecular Probes; 2.5  M) in FACS® buffer (5%
FBS in PBS with sodium azide 0.01%). After washing with
FACS® buffer, pelleted cells were resuspended in FACS® buffer
containing a precise volume of a suspension of 6- m diameter
polystyrene beads (Spherotech) and analyzed on a FACSort™
flow cytometer (Becton Dickinson) with a 488-nm argon laser.
CELLQuest™ software was used to identify live Lyt-2-positive
cells on the basis of light scatter properties, low staining by ethid-
ium (red fluorescence), and positive FITC fluorescence; beads
were identified by their distinctive combination of low forward
and high side scatter. The total number of Lyt-2-positive live
cells in the original culture was then determined from the relative
numbers of beads and positive cells identified in the analysis, the
concentration of beads in the bead suspension, and the volumes
of original cultures and aliquots. For transductions with the
vEGFP-F vector, culture aliquots were simply pelleted and resus-
pended with beads and ethidium homodimer-1, and then simi-
larly analyzed using EGFP fluorescence.
DNA Content Analysis after vEGFP-F Transductions. After
pelleting of culture aliquots and resuspension in 0.5 ml PBS each,
tubes were vortexed during addition of 3 ml of 95% ethanol. Af-
ter fixation for 15 min on ice, cells were washed once with buffer
(1% FBS in PBS with sodium azide 0.01%). Cells were then incu-
bated for 30 min at 37 C in buffer containing propidium iodide
(10  g/ml) and RNase A (0.25 mg/ml), then FACS®-analyzed
without washing.
Evaluation of Anti-Ig Toxicity. After puromycin selection,
SUDHL-6 cells transduced with vXY-Puro expressing HA-
tagged BCL–XL or empty vector were cultured with polyclonal
goat F(ab )2 fragments recognizing the Fc portion of human IgM
(Jackson ImmunoResearch Laboratories). At various durations of
culture, live cells were enumerated using reagents from the
LIVE/DEAD staining kit (Molecular Probes) and compared with
the number in matched untreated cultures. Measured aliquots of
cultures were centrifuged and the cell pellets resuspended in PBS
containing calcein AM (0.5  M), ethidium homodimer-1 (5
 M), and a precise volume of a suspension of polystyrene beads
as above. After a 10-min incubation at room temperature, the
suspensions of beads and stained cells were FACS®-analyzed as
above. Live cells were identified on the basis of light scatter,
green calcein fluorescence, and lack of staining by ethidium.
Results
Constitutive NF- B Activation Correlates with Gene Expres-
sion Profiles in Cell Lines. Previous microarray studies of
gene expression in primary tumors of DLBCL identified
two large DLBCL subgroups that differed in expression of
hundreds of genes (26). One DLBCL subgroup was termed
ABC DLBCL since it was characterized by high expression
of genes that are induced in blood B cells by BCR signal-
ing. BCR stimulation activates the NF- B pathway, and so
we reexamined our published data set specifically for the
expression of known NF-kB target genes. Many were
found to be more highly expressed in ABC-DLBCL lines
and primary tumors, and five genes were differentially ex-
pressed with a statistical significance of P   0.05. Expres-
sion of these genes is shown in Fig. 1 A, after median cen-
tering of the raw gene expression data across the spectrum
of samples illustrated. These NF- B target genes (cyclin D21864 NF- B Activity in Subtypes of Diffuse Large B Cell Lymphoma
[34], IRF-4 [13], c-FLIP [35], BCL-2 [7, 36], CCR7 [36],
and I B  [37, 38]) were highly expressed in many of the
ABC DLBCLs and tended to be poorly expressed in GCB
DLBCLs. Each of these NF- B target genes were differen-
tially expressed between the DLBCL subtypes with high
statistical significance as determined by the Student’s t test
(Fig. 1 A). Some heterogeneity in expression of the NF- B
target genes was observed among these primary tumor
specimens, which might indicate that the two major DL-
BCL subtypes that were defined previously might them-
selves include minor DLBCL subtypes that vary in the ex-
pression of NF- B target genes.
These findings suggested that activation of the NF- B
signaling pathway is a feature common to many ABC DL-
BCL cases. To investigate this possibility in depth, we
turned to DLBCL cell lines that are models for the two
DLBCL types. Two DLBCL cell lines, OCI-Ly3 and
OCI-Ly10, were shown previously to be highly related in
gene expression to ABC DLBCL tumor biopsies (26). Like
ABC DLBCL tumors, these cell lines failed to express ger-
minal center B cell “signature” genes and instead expressed
a set of genes that distinguished ABC DLBCL from GCB
DLBCL. Conversely, the SUDHL-6 cell line strongly re-
sembled GCB DLBCL tumors in gene expression (26). In
subsequent microarray experiments, several more cell lines
were found to resemble GCB DLBCLs (data not shown).
In this new data set prepared from cell lines, including new
microarray studies of OCI-Ly3, OCI-Ly10, and SUDHL-6,
we found that many known NF- B target genes were
more highly expressed in ABC-DLBCL cell lines than in
GCB DLBCL cell lines. Results for the genes used in Fig. 1
A are shown for these cell lines in Fig. 1 B, after median-
centering the raw gene expression data across the new
spectrum of samples. We also examined expression of these
NF- B target genes during normal B cell differentiation
and activation (Fig. 1 C). As expected, these genes were
Figure 1. DNA microarray analysis of NF- B target gene expression in DLBCL. Results shown are the average of two different cDNA clones used to
measure expression of each NF- B target gene. Relative expression is displayed according to the color scale shown. (A) Expression in DLBCL lymph
node biopsy samples. DLBCL cases are ordered and subdivided into GCB and ABC subtypes as defined in Fig. 1 of reference 26. (B) Expression in DLBCL
cell lines. (C) Expression in normal B cell differentiation and activation. Data and samples correspond to those used in Fig. 4 of reference 25. Lanes 1–11 are
adult blood CD19  B cells: lane 1, resting; lanes 2 and 6, anti-IgM; lanes 3 and 7, anti-IgM plus CD40L; lanes 4 and 8, anti-IgM plus IL-4; lanes 5 and
9, anti-IgM plus CD40L plus IL-4; lane 10, anti-IgM plus CD40L (low concentration); lane 11, anti-IgM plus CD40L (high concentration). Lanes 12
and 13 are tonsil germinal center B cells: lane 12, total B cells; lane 13, centroblasts. In a “time zero transformation,” the data have been normalized to
values obtained in resting blood B cells, and therefore the first column (lane 1) is entirely black.1865 Davis et al.
upregulated during activation of blood B cells by BCR
stimulation. Interestingly, normal germinal center B cells
did not express these NF- B target genes highly, which is
in keeping with the lower expression of NF- B target
genes in GCB DLBCL.
EMSAs confirmed constitutive NF- B activation in
ABC DLBCL cell lines (Fig. 2 A). Nuclear extracts of the
ABC DLBCL cell lines contained high levels of NF- B
DNA binding activity whereas two GCB DLBCL cell lines
had much lower levels; this difference was not seen in con-
trol EMSAs using Oct-1 and Sp1 probes. Addition of anti-
bodies specific for p50 to the EMSAs revealed that most of
the NF- B DNA binding activity involved heterodimers
containing the p50 NF- B1 polypeptide. Although less ap-
parent, supershifted complexes were also produced by anti-
bodies to both the p65 and c-Rel subunits in the EMSAs of
ABC DLBCL cell lines, demonstrating that these cell lines
had nuclear p50/RelA and p50/c-Rel heterodimers. In
contrast, the nuclear NF- B DNA binding activity in the
GCB cell line SUDHL-4 was much lower, and was largely
mediated by p50/c-Rel heterodimers.
Constitutive IKK Activity and I B Degradation in ABC
DLBCL Cell Lines. In normal cells, two important regu-
lators of NF- B activity are I B  and its kinase IKK. We
used an in vitro kinase assay to measure the activity of IKK
in the DLBCL cell lines, using equivalent amounts of im-
munoprecipitated IKK protein (Fig. 2, B and C). IKK from
unstimulated ABC DLBCL cell lines produced significantly
greater phosphorylation of a glutathione S-transferase-
I B  fusion protein than did IKK from the GCB DLBCL
Figure 2. NF- B and IKK kinase are
constitutively active in ABC DLBCL but
not GCB DLBCL cell lines. (A) EMSAs of
nuclear extracts from DLBCL cell lines for
NF- B DNA-binding activity. Supershift-
ing antibodies are indicated, as is the mobil-
ity of NF- B heterodimers. Arrowheads in-
dicate the position of supershifted bands.
The identity of the p50/p50 homodimer
species was established by comparison with
extracts of cells transfected with (and over-
expressing) p50 (data not shown). EMSAs
using Oct-1 and Sp1 probes showed no in-
creased binding activity in ABC DLBCL
lines relative to GCB DLBCL lines. Equiva-
lent amounts of protein (10  g) were used
for all reactions. Comparable results were
obtained with the GCB DLBCL line
SUDHL-6 (data not shown). (B) IKK kinase
assay of anti-IKK  immune complexes from
DLBCL cell lines. GST-I B  (amino acids
1–72) was substrate as follows: WT, wild-
type I B  amino acids 1–72; Mut, I B 
amino acids 1–72 with phosphoacceptor
serine residues 32 and 36 substituted by gly-
cine and alanine, respectively. Where indi-
cated, SUDHL-6 cells were activated with
anti-IgM (Jackson ImmunoResearch Labo-
ratories) for 10 min before extraction. (C)
Western blot analysis of immunoprecipitated
IKK  complexes used in B. Western blots
were developed with an antibody to IKK .1866 NF- B Activity in Subtypes of Diffuse Large B Cell Lymphoma
cell line SUDHL-6. After activation of SUDHL-6 by
cross-linking its BCR, however, IKK activity rose to levels
comparable to those observed in unstimulated ABC DL-
BCL cell lines. The specificity of the kinase activity de-
tected was confirmed by the lack of phosphorylation of a
mutant I B substrate in which the serines that are phos-
phorylated by IKK were substituted with glycine and ala-
nine residues. Therefore, in ABC DLBCL cell lines, the
greater NF- B DNA binding activity and the expression of
the NF- B target genes are likely due to constitutive activ-
ity of IKK.
This conclusion was supported by studies of I B  pro-
tein turnover in the DLBCL cell lines. Because I B  tran-
scription is itself positively regulated by NF- B activity
(37, 38), the steady-state level of I B  protein does not
necessarily reflect the rate of phosphorylation by IKK and
subsequent degradation. Indeed, full-length I B  protein is
found at comparable levels in our untreated cell lines (Fig.
3 A). However, when ABC DLBCL cell lines were treated
with cycloheximide (CHX) to block new protein synthesis,
the level of I B  declined rapidly through phosphorylation
and degradation (Fig. 3 A). By contrast, the I B  level in
SUDHL-6 was significantly more stable upon CHX treat-
ment unless the cells were also stimulated by BCR cross-
linking or by PMA and ionomycin treatment (Fig. 3 A).
Lactacystin, a drug that inhibits degradation of ubiquiti-
nated I B  by proteasomes, prevented the CHX-induced
loss of I B  in resting ABC DLBCL cell lines and in stim-
ulated SUDHL-6 cells (Fig. 3 A). In related studies, FLAG-
tagged wild-type I B  was expressed in the DLBCL cell
lines using a retroviral vector (vXY-Puro) which also trans-
lates a puromycin resistance gene located 3  of an internal
ribosomal entry site element. After retroviral transduction
and puromycin selection, polyclonal populations of in-
fected cells were studied for expression and metabolism of
FLAG-tagged I B . Wild-type FLAG-tagged I B  was
metabolized in the same manner as the native protein in
the three cell lines, with rapid degradation observed in the
ABC DLBCL cell lines (Fig. 3 B). This confirms the differ-
ences in I B  degradation rates between the cell lines
shown in Fig. 3 A and shows that these differences are not
due to possible alterations in the endogenous I B  genes in
these cell lines. Furthermore, these findings show that the
machinery for constitutive I B  degradation in ABC-
DLBCL lines is robust and is not affected by the expression
of additional exogenous wild-type IkB .
Inhibition of Constitutive NF- B Activity Is Toxic to ABC
DLBCL Cell Lines. The above studies suggested that
constitutive NF- B activation in ABC DLBCL cell lines
proceeds through a classical pathway of IKK-mediated
I B  degradation. To inhibit NF- B activation in these
cell lines, we used a “super-repressor” I B  that cannot be
phosphorylated by IKK and, as a result, can inhibit acute
induction of NF- B activity (30). In multiple attempts to
introduce this mutant I B  into ABC DLBCL lines by ret-
roviral transduction, we consistently observed that there
Figure 3. (A) Rapid, constitutive, and proteasome-dependent degradation of I B  in ABC DLBCL cell lines. Western blot analysis of I B  in ex-
tracts of CHX-treated cells (5   105 cells per lane, 20  g/ml CHX). SUDHL-6 showed stable I B  unless cells were activated for the times indicated by
PMA (Sigma-Aldrich; 40 ng/ml plus ionomycin) (Calbiochem; 2  M) (PI) or anti-IgM (50  g/ml). The more slowly migrating form of I B  (I B-P)
seen in cells treated with clastolactacystin   lactone (LC; Calbiochem, 80  M), the active metabolite of lactacystin, most likely represents phosphory-
lated I B. (B) Ectopically expressed wild-type I B  was degraded similarly to endogenous I B  in ABC and GCB DLBCL cell lines. Western blot anal-
ysis of I B  in extracts of CHX-treated cells stably transduced with retroviruses expressing FLAG epitope-tagged wild-type I B  or super-repressor
I B  (S32G/S36A) and treated with CHX with and without PI for the times indicated. In SUDHL-6, the super-repressor form of FLAG-tagged I B 
did not affect the degradation of endogenous I B  induced by PI but was itself resistant to degradation.1867 Davis et al.
were few or no surviving cells at 2 d after addition of puro-
mycin. In contrast, large numbers of surviving ABC DL-
BCL cells were obtained with the control empty retrovirus
and with a wild-type I B  retrovirus. The toxicity of the
super-repressor I B  for ABC DLBCL cell lines was selec-
tive since transduction of GCB DLBCL cell lines with this
virus and with control virus yielded comparably high num-
bers of surviving cells. In stably transduced SUDHL-6 cells,
wild-type I B  was readily degraded upon PI treatment,
but super-repressor I B  was resistant to this treatment, as
expected (Fig. 3 B).
To confirm and quantitate the toxicity of super-repressor
I B  for ABC DLBCL cells, we expressed super-repressor
I B  using a retroviral vector (vLyt-2) that also expressed
mouse Lyt-2, a surface marker not found in human cells.
After infection by vLyt-2 retroviruses, the survival and
growth of transduced cells was directly measured by flow
cytometry for Lyt-2. ABC and GCB DLBCL cell lines
were transduced with vLyt2 retroviruses expressing super-
repressor or wild-type I B , or with control virus. 2 d af-
ter infection, the three retroviruses each yielded Lyt-2-pos-
itive cells in all cell lines with comparable efficiency (data
not shown). After this time, however, the ABC DLBCL
cells transduced with the super-repressor I B  retrovirus
either declined in number or accumulated at a slower rate
than cells transduced with the wild-type I B  virus or with
control virus (Fig.4 A–F). On the other hand, GCB DL-
BCL cell lines were unaffected by transduction with super-
repressor I B  retrovirus, and increased in number expo-
nentially over time (Fig. 4 G-I). These results establish that
ABC and GCB DLBCL cell lines differ in their depen-
dence on NF- B activity for survival.
Constitutive NF- B Activation in ABC Lines Proceeds
through IKK. These results suggested that constitutive IKK
activity was necessary for survival of ABC DLBCL cells
since the super-repressor I B  that we used cannot be
phosphorylated by IKK. To test this hypothesis further, we
transduced the DLBCL cell lines with a catalytically inactive
form of IKK  that was previously shown to function as a
dominant negative inhibitor of IKK activity (39). Retroviral
transduction of this mutant IKK  was toxic to ABC DL-
BCL cell lines (Fig. 5 A, B, D, and E) but not to GCB DL-
BCL cell lines (Fig. 5 C and F). In contrast, ABC DLBCL
cell lines infected with a retrovirus expressing wild-type
IKK  or with a control retrovirus proliferated exponen-
tially. Activation of the IKK complex requires phosphoryla-
tion of serine residues 177 and 181 in an “activation loop”
of IKK  and substitution of alanine for those serines results
in a dominant negative form of IKK  (40). Retroviral
transduction of this dominant negative form of IKK  was
toxic to OCI-Ly3 and OCI-Ly10 cells but not SUDHL-6
cells (Fig. 5 G–I). In control experiments, we examined the
Figure 4. Responses of DLBCL cell lines to transduc-
tion with super-repressor I B . The results of individual
experiments are shown; those shown for the same cell line
were obtained from separate transductions performed at
different times. For each experiment, equal numbers of
cells were transduced with vLyt-2 retrovirus containing
wild-type I B , SS mutant (S32G/S36A) I B , or insert-
empty vector. For each vector, equal volumes of the same
viral supernatants were applied to the different lines. On
the days shown after transduction, live transduced cells
were quantified by flow cytometry as described in Materi-
als and Methods, using FITC-conjugated anti–mouse
CD8a (Lyt-2), ethidium, and beads. Results from each cell
line, vector, and transduction were normalized to the cor-
responding day 2 value.1868 NF- B Activity in Subtypes of Diffuse Large B Cell Lymphoma
effect of the various NF- B inhibitors on the growth of a
Hodgkin’s lymphoma cell line, L428, which has constitu-
tive nuclear NF- B that does not require IKK activity.
L428 has NF- B activity due to an inactivating mutation in
the I B  gene (20) and therefore, as would be expected,
growth of L428 was inhibited by both wild-type and super-
repressor I B  but not by the catalytically inactive domi-
nant negative form of IKK  (Fig. 5 H). Taken together,
these results demonstrate that the viability of ABC DLBCL
cell lines depends critically upon constitutive IKK activity
leading to nuclear NF- B activation of target genes.
NF- B Inhibition Causes Apoptosis and Cell-Cycle Arrest in
ABC DLBCL Lines. In many of the experiments pre-
sented above, blockade of NF- B signaling in ABC DL-
BCL cell lines resulted in a net decrease in cell numbers,
providing indirect evidence that NF- B prevents cell
death in these cells. Nevertheless, it was also possible that a
cell cycle arrest might contribute to the decreased cell
numbers after NF- B inhibition. To test this possibility,
and to provide direct evidence for cell death after NF- B
inhibition, we turned to a different retroviral vector that
had two advantages over the ones used previously. This
bicistronic vector expresses a form of EGFP modified to
contain a farnesylation signal, which we thought might fa-
cilitate the detection of dying cells given the known stabil-
ity of the EGFP protein and the membrane insertion of
the farnesylated domain. Furthermore, this retroviral con-
struct had higher transduction efficiencies, thus permitting
the recovery of sufficient transduced cells to perform an
analysis of the cell cycle. Transduction of super-repressor
I B  into ABC DLBCL cell lines using this new retroviral
vector reduced the number of live cells relative to control
cells transduced with either a wild-type I B  retrovirus or
with an empty retrovirus (Fig. 6 A). Again, super-repressor
I B  was not toxic to GCB DLBCL cell lines.
Interestingly, the histogram of EGFP fluorescence in liv-
ing transduced ABC DLBCL cells showed a shift of the cell
population over time toward lower values with the super-
repressor I B  (Fig. 6 B). This effect was not seen with
ABC DLBCL cells transduced with wild-type I B  or
empty retroviruses nor was it seen in GCB DLBCL cells
transduced with super-repressor I B  retrovirus. Since the
retroviruses used are bicistronic, it is likely that the decrease
in EGFP fluorescence reflects a parallel change in the histo-
Figure 5. Responses of DLBCL cell lines to transduc-
tion with mutant IKK . The results of individual experi-
ments are shown; those shown for the same cell line were
obtained from separate transductions performed at different
times. For each cell line, equal numbers of cells were trans-
duced with wild-type IKK , kinase-inactive mutant
(K44A) IKK , activation-loop mutant (S177A/S181/A)
IKK , or insert-empty vLyt-2 retrovirus. Hodgkin’s lym-
phoma cell line L428 was also transduced with vLyt-2
retrovirus containing forms of I B  or IKK . For each
vector, equal amounts of the same viral supernatants were
applied to the different lines. Live transduced cells were
enumerated by flow cytometry on days shown, as in Fig. 4.
Results from each cell line, vector, and transduction were
normalized to the corresponding day 2 value.1869 Davis et al.
gram of super-repressor I B  expression. This shift became
even more pronounced with time, and was also present in
earlier experiments using the vLyt2 retrovirus (data not
shown). Given that the overall numbers of ABC DLBCL
cells transduced with the super-repressor I B  retrovirus
decreased or stayed constant over time, these results sug-
gested that cells expressing high levels of EGFP and super-
repressor I B  were negatively selected from the popula-
tion due to cell death.
To provide further evidence for cell death in super-
repressor I B  transduced cells, and to evaluate cell cycle
progression, we measured DNA content by flow cytome-
try. Changes due to super-repressor I B  in ABC DLBCL
lines were most readily apparent at 4 d after transduction
(Fig. 6 C and D). Both ABC DLBCL cell lines showed a
decreased proportion of EGFP  cells corresponding to the
S and G2 M cell cycle phases, indicating a partial G1-phase
cell cycle arrest. Furthermore the cell lines showed an in-
Figure 6. Toxicity of super-repressor I B  in ABC DLBCL lines. (A) Response of ABC DLBCL lines OCI-Ly3 and OCI-Ly10, and GCB DLBCL
lines SUDHL-4 and OCI-Ly7, to transduction with bicistronic retroviruses expressing EGFP as well as wild-type I B , super-repressor SS/GA mutant
(S32G/S36A) I B , or no insert. Absolute numbers of live EGFP  cells were enumerated by flow cytometry on days shown, and normalized to the cor-
responding day 2 value. (B) Histograms of EGFP fluorescence in live transduced cells. For each cell line and day after transduction, histograms for live
EGFP  cells from the three retroviruses were normalized based on the maximum count value for each. (C) Histograms of DNA content, based on pro-
pidium iodide staining of all cells in cultures 4 d after transduction. For each cell line and retrovirus, histograms for EGFP  and EGFP  cells were nor-
malized based on the maximum count value for each. The histograms for EGFP  cells are shown shaded and filled, while EGFP  cells are shown as a
line. Results for empty retrovirus (data not shown) were similar to those for wild-type I B . (D) Relative proportions of sub-G1, G1, and G2 M phase
cells 4 d after transduction. Values are shown for the comparable EGFP  and EGFP  cells.1870 NF- B Activity in Subtypes of Diffuse Large B Cell Lymphoma
crease in cells with less than 2N DNA content, a finding
associated with apoptotic cell death. These changes were
not seen in ABC DLBCL cells transduced with wild-type
I B  or empty retroviruses, nor were they seen in GCB
DLBCL lines expressing super-repressor I B . Thus, inhi-
bition of NF- B had two effects on ABC DLBCLs: cell
cycle arrest and cell death.
Several known NF- B target genes are antiapoptotic
members of the BCL-2 family, including BCL-2 itself, A1
and BCL–XL (14, 41–46). Therefore, we tested whether
the antiapoptotic activity of BCL-2 family members could
protect ABC DLBCL cells against the toxicity caused by
inactivating NF- B. OCI-Ly3 and OCI-Ly10 cells were
first transduced with control or BCL–XL-expressing vXY-
Puro retroviruses; after puromycin selection, resistant cells
were superinfected with vLyt-2 retroviruses expressing
I B  (wild-type or super-repressor) or with control vLyt-2
retrovirus. BCL–XL afforded no protection against the
toxic effects of super-repressor I B  (Fig. 7 A), despite the
fact that the transduced OCI-Ly3 and OCI-Ly10 cells ex-
pressed high levels of BCL–XL protein (Fig. 7 B). Like-
wise, transduction of OCI-Ly3 cells with retroviruses
expressing A1 and BCL-2 did not block the effects of su-
per-repressor I B  (data not shown). In control experi-
ments, we found that retrovirally mediated expression of
BCL–XL was able to protect SUDHL-6 cells against apop-
tosis caused by cross-linking of the surface Ig receptor,
demonstrating that this retrovirus can express functionally
meaningful levels of BCL–XL (Fig. 7 B and C). These re-
sults demonstrate that the prosurvival effect of NF- B in
ABC DLBCL cell lines is likely due to the activity of multi-
ple NF- B target genes, and cannot be simply mimicked by
expression of a single antiapoptotic BCL-2 family member.
Discussion
Recently, gene expression profiling was able to stratify
DLBCL patients into two subgroups that had markedly di-
vergent clinical outcomes after multiagent chemotherapy
(26). However, given the extensive differences in gene ex-
pression between these two DLBCL subtypes, it was not
clear which individual genes or signaling pathways contrib-
uted critically to this biological and clinical dichotomy.
ABC DLBCL tumors expressed genes that are characteristi-
cally activated in blood B cells by signaling through the
BCR. One of the signaling pathways prominently engaged
after BCR stimulation is the NF- B pathway, and ABC
DLBCLs frequently expressed NF- B target genes highly.
Conversely, GCB DLBCLs generally had low expression
of NF- B target genes, as did normal germinal center B
cells, from which this DLBCL subtype is putatively de-
rived. Two DLBCL cell lines were indistinguishable in
gene expression from ABC DLBCL tumors overall, and
consequently expressed NF- B targets highly. We found
that these cell lines had constitutive nuclear NF- B, I B 
degradation, and IKK activity, whereas cell lines derived
from GCB DLBCL lacked this evidence of NF- B path-
way activation. Most importantly, dominant interference
with the NF- B pathway was toxic to ABC DLBCL cells,
but not to GCB DLBCL cells, thus validating NF- B and
Figure 7. BCL-2 family members fail to block the toxicity of NF- B in-
hibition. (A) The indicated ABC DLBCL cell lines were transduced with
vXY-Puro retrovirus expressing BCL–XL or control retrovirus and puro-
mycin-selected, then transduced with vLyt-2 retrovirus expressing forms of
I B  or control retrovirus. Live vLyt2-transduced cells were quantitated as
indicated in the legend to Fig. 4. Values represent the average of two experi-
ments with BCL–XL-transduced lines and three with control lines. (B) West-
ern blot analysis for expression of endogenous and transduced (HA-tagged) BCL–XL,
probed with antibody to BCL–XL COOH terminus. Lines transduced with vXY-Puro
retrovirus expressing BCL–XL were puromycin-selected. Other lines shown were untrans-
duced, including RC-K8, a DLBCL line with high expression of endogenous BCL–XL
mRNA and protein. (C) Effect of BCL–XL on survival of SUDHL-6 after BCR cross-
linking. In cells transduced with BCL–XL or control retrovirus, the number of live cells in
cultures treated with anti-IgM was compared with that in matched untreated cultures.1871 Davis et al.
its upstream activating pathways as molecular targets in
ABC DLBCL.
There are two general models to explain the constitutive
NF-kB activation in ABC DLBCL. The first is that ABC
DLBCLs may be derived from a B cell differentiation stage
at which NF- B is normally activated. Although the cell of
origin of ABC DLBCL has not been clearly defined, a re-
cently described minor germinal center B cell subtype is an
intriguing candidate. Approximately 5% of germinal center
B cells show decreased expression of BCL-6, increased ex-
pression of Blimp-1 and expression of IRF-4 (47, 48), all
features of ABC DLBCL. These cells also have a plasma-
cytic morphology suggesting that they may be intermedi-
ates on the path to terminal plasmacytic differentiation. If
ABC DLBCLs are derived from this cell type, then the ac-
tivity of NF- B in these tumors may reflect the physiolog-
ical use of this pathway at this differentiation stage.
In an alternative model, the activation of NF- B is an
oncogenic event that occurs in ABC DLBCLs and is unre-
lated to the physiological role of NF- B in B cell differen-
tiation. Indeed, the avian retrovirus v-rel gene encodes a
potent oncogene that causes lymphoid tumors in chickens
(49), and recently it has been shown that human c-Rel can
also transform primary chicken spleen cells (50). The ge-
nomic locus containing the human c-rel gene is amplified
and overexpressed in 23% of DLBCLs (51), especially in
those arising in extranodal sites, but the mechanistic signifi-
cance of this is unknown. Another relatively rare genomic
event in B cell malignancies is alteration of the NF- B2
gene by translocation and deletion of its 3  end (22, 23,
52). Removal of the 3  end of the NF- B2 gene increases
the NF- B2 mRNA expression and deletes the COOH-
terminal transrepression domain of NF- B2, creating a
constitutive activator of transcription (53, 54) that can
transform 3T3 fibroblasts (55). These relatively infrequent
genomic modifications of the c-rel and NF- B2 loci are un-
likely to account for the activation of the NF- B pathway
in ABC DLBCL since this DLBCL subtype accounts for
about half of all DLBCLs (26), and since no overexpression
of the c-rel or NF- B2 genes is evident in ABC DLBCLs
(data not shown).
NF- B family members can, in some cases, function as
transforming oncogenes, but their primary role in malig-
nant transformation may be to prevent apoptosis that can
be caused by various other oncogenes. For example, trans-
formation by activated ras, BCR-ABL and by the HTLV-I
tax protein requires activation of the NF- B pathway (56–
59). Each of these oncogenes activates signaling pathways
that can trigger apoptosis, but they also activate NF- B, di-
rectly or indirectly, thereby preventing apoptosis and pro-
moting cellular transformation. Other oncogenes such as
c-myc cause apoptosis and not cellular transformation under
conditions of growth factor deprivation (60), and NF- B
activation by serum-derived PDGF can protect cells against
this apoptosis (61). These observations suggest an intriguing
hybrid model to explain NF-kB activation in ABC DL-
BCL: physiological NF- B activation at a particular stage
of B cell differentiation might permit certain oncogenic
events to occur that would otherwise cause apoptosis in the
absence of NF-kB. From this perspective, the normal in-
duction of NF- B during immune responses might be
viewed as a predisposing event to lymphoma formation.
In keeping with the established ability of the NF- B
pathway to prevent cell death (14), inhibition of this path-
way in ABC DLBCL cell lines decreased cell numbers and
caused the appearance of cells with sub-genomic DNA
content. However, the mechanisms underlying this pro-
survival effect of NF- B are likely to be multifactorial. In
various cell types, NF- B can transcriptionally induce one
or more antiapoptotic BCL-2 family members, including
A1, BCL-2, and BCL–XL, and ABC DLBCL cell lines ex-
press BCL-2 (Fig. 1 B) and A1 (data not shown). Forced
expression of A1 or BCL–XL alone have been reported to
protect multiple cell types against apoptosis after NF- B
inhibition (14, 45, 46, 62). Given these considerations, we
were surprised that forced expression of BCL-2, A1, or
BCL-XL did not affect the toxicity of NF- B inhibition to
ABC DLBCL cell lines. However, it has been shown that
in certain contexts, the simultaneous expression of multiple
antiapoptotic NF- B target genes is required to protect
against apoptosis induced after NF- B inhibition, and some
of these (TRAF1, TRAF2, c-IAP1, and c-IAP2) are not
BCL-2 family members (63). Furthermore, it is possible
that primary activation of the NF- B pathway in ABC
DLBCLs initiates an elaborate regulatory cascade that es-
tablishes a new signaling homeostasis within the cell, in-
cluding pathways other than NF- B.
In addition to its survival effects, activity of the NF- B
pathway was necessary for cell cycle progression in ABC
DLBCLs. NF- B inhibition resulted in a G1-phase cell cy-
cle arrest of these cells, implying that primary or secondary
targets of NF- B are required for their cell cycle progres-
sion. The NF- B target gene cyclin D2 is a potential medi-
ator of these effects, given that D-type cyclins are required
for progression beyond G1 phase, and that cyclin D2 ex-
pression is highly characteristic of ABC DLBCL cell lines
and primary tumors. Furthermore, induction of cyclin D2
expression is required for the proliferative response of B
cells to BCR activation (64), which is especially significant
given that the gene expression profile of ABC DLBCL re-
sembles that of BCR-activated B cells. Regardless of the
specific cause, cell-cycle arrest itself causes apoptosis in
many types of tumor cells, and the loss of NF- B–driven
proliferative factors (such as cyclin D2) may therefore con-
tribute to the cytoxicity of NF- B inhibitors in ABC DL-
BCL lines.
The nuclear NF- B activity in ABC DLBCL cell lines
results from constitutive IKK activity, but the upstream sig-
naling pathways activating IKK in these cells are not yet
clear. Most known NF- B activating stimuli lead to phos-
phorylation of IKK  in a regulatory loop of the kinase do-
main (3, 40, 65). This mechanism is also likely to account
for IKK activity in ABC DLBCL since a dominant nega-
tive version of IKK  with mutations in this loop was toxic
to these cells. A multitude of signaling pathways lead to ac-
tivation of IKK (2, 4). Signaling through the BCR activates1872 NF- B Activity in Subtypes of Diffuse Large B Cell Lymphoma
phospholipase C 2, BLNK, and Btk which appear to act in
concert to activate IKK (66–69). ABC DLBCLs express
many genes in common with BCR-stimulated blood B
cells, beyond just the NF- B target genes (26). Thus, con-
stitutive activation of NF- B in ABC DLBCL may be due
to a signaling cascade that mimics BCR stimulation and
leads to IKK activation. A future understanding of the up-
stream signaling pathway that leads to IKK activation in
ABC DLBCL may provide new molecular targets for phar-
macological intervention in this disease.
Finally, our results demonstrate the power of gene ex-
pression profiling to reveal the activity of signaling path-
ways in cancer that are potentially therapeutic targets. The
present observation that ABC DBLCL, but not GCB DL-
BCL, often engages the NF- B pathway, validates the
view that these lymphoma subtypes are distinct disease en-
tities that have disparate pathogenetic mechanisms. We ob-
served previously that these subtypes were also quite differ-
ent in the overall clinical course of patients, but it is
important to emphasize that this clinical difference oc-
curred in the context of multiagent, anthracycline-based
chemotherapy (26). In this regard, the ability of NF- B to
inhibit responses to cancer therapeutic agents (15) may
contribute to the refractory clinical behavior of ABC DL-
BCL. Furthermore, inhibition of NF- B can synergize
with chemotherapy to kill tumor cells (15). Thus, we pro-
pose that clinical trials should be initiated in DLBCL in
which chemotherapy is combined with pharmacological
inhibition of the NF- B pathway (70, 71), and that these
trials should include gene expression profiling of the tumor
cells to correlate the response of the patients with the mo-
lecular phenotype of their cancers. In this fashion, pretreat-
ment gene expression profiling in DLBCL may ultimately
be used to identify which pathogenic signaling pathways
are active in a particular case, allowing the appropriate
choice of specific therapy to be made.
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